Literature DB >> 10851081

DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma.

H Maacke1, K Jost, S Opitz, S Miska, Y Yuan, L Hasselbach, J Lüttges, H Kalthoff, H W Stürzbecher.   

Abstract

Molecular processes that could contribute to differences in chemo- and radioresistance include variations in DNA repair mechanisms. In mammalian cells, the product of the rad51 gene mediates DNA repair via homologous recombination. We describe that in contrast to conventional monolayer cell systems Rad51 protein accumulates to high-levels in three-dimensional cell culture models as well as in orthotopic xeno-transplants of human pancreatic cancer cells. Strikingly, over-expression of wild-type Rad51 was also found in 66% of human pancreatic adenocarcinoma tissue specimens. Functional analysis revealed that Rad51 over-expression enhances survival of cells after induction of DNA double strand breaks. These data suggest that perturbations of Rad51 expression contribute to the malignant phenotype of pancreatic cancer. Oncogene (2000).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10851081     DOI: 10.1038/sj.onc.1203578

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  63 in total

1.  Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.

Authors:  Meredith A Morgan; Leslie A Parsels; Lili Zhao; Joshua D Parsels; Mary A Davis; Maria C Hassan; Sankari Arumugarajah; Linda Hylander-Gans; Deborah Morosini; Diane M Simeone; Christine E Canman; Daniel P Normolle; Sonya D Zabludoff; Jonathan Maybaum; Theodore S Lawrence
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

2.  High levels of RAD51 perturb DNA replication elongation and cause unscheduled origin firing due to impaired CHK1 activation.

Authors:  Ann Christin Parplys; Jasna Irena Seelbach; Saskia Becker; Matthias Behr; Agnieszka Wrona; Camilla Jend; Wael Yassin Mansour; Simon Andreas Joosse; Horst-Werner Stuerzbecher; Helmut Pospiech; Cordula Petersen; Ekkehard Dikomey; Kerstin Borgmann
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

3.  Synthesis, molecular modeling, and biological evaluation of novel RAD51 inhibitors.

Authors:  Jiewen Zhu; Hongyuan Chen; Xuning Emily Guo; Xiao-Long Qiu; Chun-Mei Hu; A Richard Chamberlin; Wen-Hwa Lee
Journal:  Eur J Med Chem       Date:  2015-04-09       Impact factor: 6.514

4.  Rad51 promoter-targeted gene therapy is effective for in vivo visualization and treatment of cancer.

Authors:  Christopher M Hine; Andrei Seluanov; Vera Gorbunova
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

5.  HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination.

Authors:  Shanthi Adimoolam; Mint Sirisawad; Jun Chen; Patti Thiemann; James M Ford; Joseph J Buggy
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-27       Impact factor: 11.205

6.  Multipotent hematopoietic cells susceptible to alternative double-strand break repair pathways that promote genome rearrangements.

Authors:  Richard Francis; Christine Richardson
Journal:  Genes Dev       Date:  2007-05-01       Impact factor: 11.361

Review 7.  The consequences of Rad51 overexpression for normal and tumor cells.

Authors:  Hannah L Klein
Journal:  DNA Repair (Amst)       Date:  2008-02-01

8.  DNA repair by homologous recombination, but not by nonhomologous end joining, is elevated in breast cancer cells.

Authors:  Zhiyong Mao; Ying Jiang; Xiang Liu; Andrei Seluanov; Vera Gorbunova
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

9.  Overexpression of RAD51 occurs in aggressive prostatic cancer.

Authors:  Anita Mitra; Charles Jameson; Yolanda Barbachano; Lydia Sanchez; Zsofia Kote-Jarai; Susan Peock; Nayanta Sodha; Elizabeth Bancroft; Anne Fletcher; Colin Cooper; Douglas Easton; Rosalind Eeles; Christopher S Foster
Journal:  Histopathology       Date:  2009-12       Impact factor: 5.087

10.  Dysfunctional homologous recombination mediates genomic instability and progression in myeloma.

Authors:  Masood A Shammas; Robert J Shmookler Reis; Hemanta Koley; Ramesh B Batchu; Cheng Li; Nikhil C Munshi
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.